Analyst Rating: Will Nabriva Therapeutics PLC - ADR (NBRV) Stock Do Better Than the Market?

Friday, November 12, 2021 11:35 AM | InvestorsObserver Analysts

Mentioned in this article

Analyst Rating: Will Nabriva Therapeutics PLC - ADR (NBRV) Stock Do Better Than the Market?

Wall Street is positive on Nabriva Therapeutics PLC - ADR (NBRV). On average, analysts give NBRV a Buy rating. The average price target is $2.675, which means analysts expect the stock to rise by 157.21% over the next twelve months. That average ranking earns NBRV an Analyst Rating of 20, which is better than 20% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating NBRV a Buy today. Find out what this means to you and get the rest of the rankings on NBRV!

See Full NBRV Report

Why are Analyst Ratings Important?

Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers. InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.

What's Happening With Nabriva Therapeutics PLC - ADR Stock Today?

Nabriva Therapeutics PLC - ADR (NBRV) stock is lower by -6.96% while the S&P 500 has gained 0.61% as of 11:34 AM on Friday, Nov 12. NBRV is down -$0.08 from the previous closing price of $1.12 on volume of 819,828 shares. Over the past year the S&P 500 is up 32.25% while NBRV is down -75.41%. NBRV lost -$2.13 per share the over the last 12 months. Click Here to get the full Stock Report for Nabriva Therapeutics PLC - ADR stock.